Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked hard but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my last several shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire interview which I came away with a poor opinion of the company.

Irony of irony, my poor opinion of the business has grown steadily, although the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and associated intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) and the first new drug program approval ($five million), as well as royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and many indications, it’s this individual therapies and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on its site (below) shows an active organization with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple delivering presentations.

Could it all be smoke and mirrors? That is a question I have been asking myself from the really beginning of the interest of mine in this company. Judging by the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *